Showing results (1-10 of 247) with videos related to
Sort By:
Pageof 25
Clinical Lymphoma & Myeloma|September 26, 2009
What are the endpoints of therapy for acute leukemias? Old definitions and new challengesB Douglas Smith, Judith E KarpClinical Advances in Hematology & Oncology : H&O|September 17, 2005
New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulationTing Bao, B Douglas Smith, Judith E KarpPharmacogenomics|August 28, 2012
The clinically relevant pharmacogenomic changes in acute myelogenous leukemiaAshkan Emadi, Judith E KarpClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicineIvana Gojo, Judith E KarpStem Cells Translational Medicine|March 16, 2017
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex VivoKatherine L B Knorr, Laura E Finn, B Douglas Smith, et al.Cancer Discovery|December 12, 2013
Personalized therapy for acute myeloid leukemiaChristopher S Hourigan, Judith E KarpCurrent Opinion in Hematology|May 27, 2009
Novel postremission strategies in adults with acute myeloid leukemiaJeffrey E Lancet, Judith E KarpCurrent Opinion in Investigational Drugs (London, England : 2000)|May 25, 2010
Development of therapeutic agents for older patients with acute myelogenous leukemiaChristopher S Hourigan, Judith E KarpOncology (Williston Park, N.Y.)|September 1, 2005
Farnesyl transferase inhibitors in myeloid disordersJeffrey E Lancet, Judith E KarpNature Reviews. Clinical Oncology|June 27, 2013
Minimal residual disease in acute myeloid leukaemiaChristopher S Hourigan, Judith E KarpPageof 25